Drug Profile
Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical
Alternative Names: Anti-sclerostin-monoclonal-antibody-Mereo; BPS-804; UX-143Latest Information Update: 17 Oct 2023
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Developer Mereo BioPharma; Novartis; Ultragenyx Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Osteogenesis imperfecta
- Discontinued Hypophosphatasia; Postmenopausal osteoporosis
Most Recent Events
- 14 Oct 2023 Efficacy and adverse event data from a phase II/III trial in Osteogenesis imperfecta released by Ultragenyx Pharmaceutical
- 14 Jun 2023 Phase-III clinical trials in Osteogenesis imperfecta (In children) in Italy, Canada, Brazil (IV) (NCT05768854)
- 14 Jun 2023 Phase-III clinical trials in Osteogenesis imperfecta (In children) in Poland, Netherlands, France (IV) (NCT05768854)